

Ref: Syn/CS/SE/SAST/2021-22/Apr/07

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 08, 2021

To, The Manager Listing The BSE Limited Corporate Service Department Floor 25, P J Towers, Dalal Street, Mumbai 400 001	To, The Manager Listing The National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra – Kurla Complex, Bandra (East), Mumbai- 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Sub: Annual Disclosure under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011 submitted by Promoter(s) of the Company

Dear Sir/Madam,

This is with reference to the disclosure required under Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations") regarding aggregate shareholding and voting rights held by the promoter(s), member of promoter group and PAC with him as of the March 31, 2021.

We are enclosing herewith the said disclosures given by Promoter(s) of the Company as on March 31, 2021 relating to Syngene International Limited in the prescribed format.

Request to kindly take this intimation on record.

Yours faithfully,

For **Syngene International Limited**

**PRIYADARSHI
NI
MAHAPATRA**

Digitally signed by PRIYADARSHINI
MAHAPATRA
DN: c=IN, o=Personal,
2.5.4.20=98524f9d9130962f80a142e6c4ee41de
2a31ebbe4aca99a554bc2a1b35b665b0,
postalCode=400607, st=MAHARASHTRA,
serialNumber=df67e39aa5435d22f718c22d051
6d97afb1208536f4f1860285e06c72d0c9992,
cn=PRIYADARSHINI MAHAPATRA
Date: 2021.04.08 22:39:37 +05'30'

Priyadarshini Mahapatra

Company Secretary & Compliance Officer

Enclosed: Disclosure under regulation 30(1) & 30(2) of SEBI (SAST) Regulation, 2011 submitted by Promoter(s) to the Company.



Biocon Limited

20th KM Hosur Road

Electronics City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

April 7, 2021

To,
The Manager Listing
The BSE Limited,
Corporate Service Department
Floor 25, P J Towers,
Dalal Street, Mumbai 400 001
Scrip Code: 532523

To,
The Manager Listing
The National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra – Kurla Complex, Bandra (East),
Mumbai- 400 051
Scrip Symbol: BIOCON

To,
Syngene International Limited
Biocon Park SEZ, Bommasandra Industrial Area
Phase IV Bommasandra, Jigani Link Road,
Bengaluru-560099

Sub: Annual Disclosure under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011

Dear Sir/Madam,

This is with reference to the disclosure required under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations") regarding aggregate shareholding and voting rights held by the promoter(s), member of promoter group and PAC with him as on March 31, 2021.

We are enclosing herewith the said disclosures as on March 31, 2021 relating to Syngene International Limited in the prescribed format.

Request to kindly take this intimation on record.

Yours faithfully,

For **Biocon Limited**

Siddharth Mittal
Managing Director and CEO



Enclosed: Disclosure under regulation 30(1) & 30(2) of SEBI (SAST) Regulation, 2011

Email to: BSE: corp.relations@bseindia.com and NSE: takeover@nse.co.in


ANNEXURE – 1

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1	Name of the Target Company (TC)	Syngene International Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	1. National Stock Exchange of India Limited 2. BSE Limited		
3	Particulars of the shareholder(s) : a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. <p align="center">OR</p> b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Promoter(s) 1. M/s. Biocon Limited Promoter Group 2. M/s. Biocon Research Limited* 3. M/s. Biocon Limited Employee Welfare Trust 4. Ms. Kiran Mazumdar Shaw 5. Ms. Yamini R Mazumdar 6. Mr. Dev Mazumdar 7. Prof. Ravi Rasendra Mazumdar & Prof. Catherine Patricia Rosenberg		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
	As of March 31, 2021, holding of:			
	a. Shares			
	1. M/s. Biocon Limited	28,09,74,772	70.24%	NA
	2. M/s. Biocon Research Limited*	-	-	-
	3. M/s. Biocon Limited Employee Welfare Trust	13,19,083	0.33%	NA
	4. Ms. Kiran Mazumdar Shaw	15,276	0.00%	NA
	5. Ms. Yamini R Mazumdar	20,060	0.01%	NA
	6. Mr. Dev Mazumdar	7,000	0.00%	NA
	7. Prof. Ravi Rasendra Mazumdar & Prof. Catherine Patricia Rosenberg	2,120	0.00%	NA
	b. Voting Rights (otherwise than by shares)	NIL	NIL	NIL
	c. Warrants,	NIL	NIL	NIL
	d. Convertible Securities	NIL	NIL	NIL
	e. Any other instrument that would entitle the holder to receive shares in the TC.	NIL	NIL	NIL
	Total	28,23,38,311	70.58%	NA

* Biocon Research Limited merged with Biocon Biologics India Limited vide order dated February 4, 2020 by the Bengaluru Bench of National Company Law Tribunal ("NCLT").



Part-B**

Name of the Target Company: Syngene International Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group	PAN of the person and PACs
M/s Biocon Limited	Yes	
M/s Biocon Research Limited*	Yes	
M/s Biocon Limited Employee Welfare Trust	Yes	
Ms. Kiran Mazumdar Shaw	Yes	
Ms. Yamini R Mazumdar	Yes	
Mr. Dev Mazumdar	Yes	
Prof. Ravi Rasendra Mazumdar & Prof. Catherine Patricia Rosenberg	Yes	

For Biocon Limited



Siddharth Mittal
Managing Director and CEO



Place: Bengaluru

Date: April 7, 2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.